Florian Voß
About
Florian Voß is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Applied Mathematics.
According to data from OpenAlex, Florian Voß has authored 54 papers receiving a total of 928 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 22 papers in Physiology and 7 papers in Applied Mathematics. Recurrent topics in Florian Voß's work include Chronic Obstructive Pulmonary Disease (COPD) Research (25 papers), Asthma and respiratory diseases (16 papers) and Respiratory Support and Mechanisms (11 papers). Florian Voß is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (25 papers), Asthma and respiratory diseases (16 papers) and Respiratory Support and Mechanisms (11 papers). Florian Voß collaborates with scholars based in Germany, United States and United Kingdom. Florian Voß's co-authors include Toby M. Maher, Lars Grönke, Susanne Stowasser, Vincent Cottin, Claudia Valenzuela, Gary T. Ferguson, Marlies Wijsenbeek, Catherine Gloaguen, Luca Richeldi and Arata Azuma and has published in prestigious journals such as New England Journal of Medicine, Blood and PLoS ONE.
In The Last Decade
Florian Voß
53 papers receiving 902 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Florian Voß Germany | 17 | 484 | 300 | 219 | 132 | 94 | 54 | 928 | ||
| Sabine Leh Norway | 23 | 229 0.5× | 181 0.6× | 267 1.2× | 90 0.7× | 225 2.4× | 85 | 1.3k | ||
| Eduard J. van Beers Netherlands | 25 | 183 0.4× | 619 2.1× | 284 1.3× | 783 5.9× | 38 0.4× | 109 | 1.6k | ||
| Martin Jenkins United Kingdom | 16 | 409 0.8× | 210 0.7× | 207 0.9× | 33 0.3× | 150 1.6× | 54 | 956 | ||
| Sebastian Martini Germany | 17 | 116 0.2× | 171 0.6× | 373 1.7× | 35 0.3× | 29 0.3× | 44 | 1.0k | ||
| Jie Wu China | 22 | 240 0.5× | 46 0.2× | 505 2.3× | 87 0.7× | 190 2.0× | 104 | 1.5k | ||
| Harold G. Sutton United States | 23 | 389 0.8× | 87 0.3× | 394 1.8× | 57 0.4× | 447 4.8× | 47 | 1.6k | ||
| Ji Lin United States | 19 | 160 0.3× | 233 0.8× | 352 1.6× | 13 0.1× | 380 4.0× | 50 | 1.1k | ||
| Mäneka Puligandla United States | 13 | 256 0.5× | 26 0.1× | 185 0.8× | 89 0.7× | 117 1.2× | 42 | 759 | ||
| Stacey Tannenbaum United States | 13 | 115 0.2× | 209 0.7× | 233 1.1× | 94 0.7× | 29 0.3× | 24 | 840 |
Countries citing papers authored by Florian Voß
Since
Specialization
Citations
This map shows the geographic impact of Florian Voß's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florian Voß with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florian Voß more than expected).
Fields of papers citing papers by Florian Voß
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Florian Voß. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florian Voß. The network helps show where Florian Voß may publish in the future.
Co-authorship network of co-authors of Florian Voß
This figure shows the co-authorship network connecting the top 25 collaborators of Florian Voß. A scholar is included among the top collaborators of Florian Voß based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florian Voß. Florian Voß is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Maher, Toby M., Shervin Assassi, Arata Azuma, et al.. (2025). Nerandomilast in Patients with Progressive Pulmonary Fibrosis. New England Journal of Medicine. 392(22). 2203–2214.
2.
Maher, Toby M., Kevin K. Brown, Steve Cunningham, et al.. (2024). Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach. Pediatric Pulmonology. 59(4). 1038–1046.
3.
Maher, Toby M., Shervin Assassi, Arata Azuma, et al.. (2023). Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respiratory Research. 10(1). e001580–e001580.
4.
Maher, Toby M., Susanne Stowasser, Florian Voß, et al.. (2023). Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis. Respirology. 28(12). 1147–1153.
5.
Bonella, Francesco, Vincent Cottin, Claudia Valenzuela, et al.. (2022). Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Advances in Therapy. 39(7). 3392–3402.
6.
Deterding, Robin R., Matthias Griese, Gail Deutsch, et al.. (2021). Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ Open Research. 7(2). 805–2020.
7.
Martínez, Fernando J., R Abrahams, Gary T. Ferguson, et al.. (2019). Effects of baseline symptom burden on treatment response in COPD. International Journal of COPD. Volume 14. 181–194.
8.
Lenz, Heinz‐Josef, Guillem Argilés, Takayuki Yoshino, et al.. (2019). Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. Clinical Colorectal Cancer. 18(4). 269–279.e5.
9.
Maltais, François, Alan Hamilton, Florian Voß, & M. Reza Maleki-Yazdi. (2019). Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD. Advances in Therapy. 36(4). 962–968.
10.
Koch, Andrea, Henrik Watz, M. Reza Maleki-Yazdi, et al.. (2017). Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol. npj Primary Care Respiratory Medicine. 27(1). 60–60.
11.
Maltais, François, et al.. (2016). Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies. Respiratory Research. 17(1). 77–77.
12.
Buhl, Roland, Sheldon Magder, Ulrich Bothner, et al.. (2016). Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine. 122. 58–66.
13.
Ferguson, Gary T., Jill P. Karpel, Emmanuelle Clerisme-Beaty, et al.. (2016). <p>Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO<sup>®</sup> and OTEMTO<sup>®</sup> studies: a subgroup analysis by age</p>. International Journal of COPD. Volume 11. 2701–2710.
14.
Asselah, Tarik, Stefan Zeuzem, Vincent Soriano, et al.. (2015). ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS ONE. 10(12). e0144004–e0144004.
15.
Abrahams, R, Gary T. Ferguson, Emmanuelle Clerisme-Beaty, et al.. (2015). Effect of Tiotropium + Olodaterol on the Use of Nighttime Rescue Medication in Patients With COPD: Results From Four Randomized, Double-Blind Studies. CHEST Journal. 148(4). 731A–731A.
16.
Ferguson, Gary T., Emmanuelle Clerisme-Beaty, Florian Voß, et al.. (2015). Tiotropium + Olodaterol Provides Improvements in SGRQ and Dyspnea Compared With Monotherapy Components in Patients With COPD: Results From Four Randomized, Double-Blind Studies. CHEST Journal. 148(4). 726A–726A.
17.
Zeuzem, Stefan, Vincent Soriano, Tarik Asselah, et al.. (2014). Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. Antimicrobial Agents and Chemotherapy. 59(2). 1282–1291.
18.
Voß, Florian, Catherine Gloaguen, & Volker Schmidt. (2010). Scaling limits for shortest path lengths along the edges of stationary tessellations. Advances in Applied Probability. 42(4). 936–952.
19.
Gloaguen, Catherine, Florian Voß, & Volker Schmidt. (2009). Parametric distance distributions for fixed access network analysis and planning. 1–8.
20.
Quaschning, Thomas, Florian Voß, Katharina Relle, et al.. (2007). Lack of Endothelial Nitric Oxide Synthase Promotes Endothelin-Induced Hypertension. Journal of the American Society of Nephrology. 18(3). 730–740.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sabine Leh Breakdown of academic impact, for papers by Eduard J. van Beers Breakdown of academic impact, for papers by Martin Jenkins Breakdown of academic impact, for papers by Sebastian Martini Breakdown of academic impact, for papers by Jie Wu Breakdown of academic impact, for papers by Harold G. Sutton Breakdown of academic impact, for papers by Ji Lin Breakdown of academic impact, for papers by Mäneka Puligandla Breakdown of academic impact, for papers by Stacey Tannenbaum